adamantane has been researched along with Kidney Failure in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (87.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Furihata, K; Kaneko, Y; Katashima, M; Miyatake, D; Nishimura, T; Oda, K; Sekino, H; Shibata, M; Shibata, T; Urae, A | 1 |
| He, YL; Kulmatycki, K; Ligueros-Saylan, M; Reynolds, C; Taylor, A; Zhang, Y; Zhou, W | 1 |
| Davis, TM | 1 |
| Dongre, N; Groop, PH; Kothny, W | 1 |
| Bhatt, DL; Braunwald, E; Cavender, MA; Corbalan, R; Davidson, JA; Frederich, R; He, P; Hirshberg, B; Im, K; Leiter, LA; McGuire, DK; Mosenzon, O; Nicolau, JC; Raz, I; Scirica, BM; Steg, PG; Udell, JA; Umez-Eronini, AA | 1 |
| Baruah, MP; Gupta, A; Gupta, Y; Kalra, S | 1 |
| Bhatt, DL; Braunwald, E; Cahn, A; Hirshberg, B; Im, K; Iqbal, N; Kanevsky, E; Leibowitz, G; Mosenzon, O; Raz, I; Rozenberg, A; Scirica, BM; Sjostrand, M; Stahre, C; Yanuv, I | 1 |
| Boulton, DW; Castaneda, L; Frevert, EU; Kornhauser, DM; Li, L; Patel, CG; Tang, A; Vachharajani, NN | 1 |
1 review(s) available for adamantane and Kidney Failure
| Article | Year |
|---|---|
Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment.
Topics: Adamantane; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Glycated Hemoglobin; Humans; Piperidines; Renal Insufficiency; Risk Factors; Treatment Outcome; Uracil | 2014 |
3 trial(s) available for adamantane and Kidney Failure
| Article | Year |
|---|---|
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial.
Topics: Adamantane; Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptides; Female; Heart Failure; Hospitalization; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Renal Insufficiency; Severity of Illness Index; Stroke; Treatment Outcome | 2015 |
Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 Trial.
Topics: Adamantane; Aged; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptides; Female; Follow-Up Studies; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin, Short-Acting; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Renal Insufficiency; Risk Factors; Sulfonylurea Compounds | 2016 |
Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin.
Topics: Adamantane; Adult; Aged; Diabetes Mellitus, Type 2; Dialysis Solutions; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Half-Life; Hepatic Insufficiency; Humans; Hypoglycemic Agents; Kidney Failure, Chronic; Male; Metabolic Clearance Rate; Middle Aged; Renal Dialysis; Renal Insufficiency; Severity of Illness Index | 2011 |
4 other study(ies) available for adamantane and Kidney Failure
| Article | Year |
|---|---|
Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects with Normal and Impaired Renal Function.
Topics: Adamantane; Administration, Oral; Adult; Aged; Female; Humans; Janus Kinase Inhibitors; Male; Middle Aged; Niacinamide; Renal Insufficiency; Young Adult | 2020 |
Pharmacokinetics of vildagliptin in patients with varying degrees of renal impairment.
Topics: Adamantane; Adult; Aged; Area Under Curve; Body Mass Index; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Male; Middle Aged; Nitriles; Pyrrolidines; Renal Insufficiency; Vildagliptin | 2013 |
Vildagliptin in patients with type 2 diabetes mellitus and renal impairment.
Topics: Adamantane; Blood Glucose; Creatinine; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Male; Nitriles; Pyrrolidines; Renal Insufficiency; Vildagliptin | 2014 |
Comment on Udell et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial. Diabetes Care 2015;38:696-705.
Topics: Adamantane; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptides; Female; Humans; Male; Renal Insufficiency | 2015 |